Kalydeco Approved in Europe to Treat Children with R117H Mutation

The European Commission has approved Vertex’s Kalydeco (ivacaftor) for the treatment of children and adolescents with cystic fibrosis (CF) who carry the R117H mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which is defective in CF. Kalydeco previously was...